Joe-Marc Chauvin - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Joe-Marc Chauvin

Showing results (11-20 of 15) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 15 results.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2018

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced MelanomaDiwakar Davar, Hong Wang, Joe-Marc Chauvin, et al.

The Journal of Clinical Investigation|March 22, 2022

Tim-3 mediates T cell trogocytosis to limit antitumor immunityOrnella Pagliano, Robert M Morrison, Joe-Marc Chauvin, et al.

Nature Medicine|March 1, 2022

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1John A McCulloch, Diwakar Davar, Richard R Rodrigues, et al.

Science (New York, N.Y.)|February 5, 2021

Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patientsDiwakar Davar, Amiran K Dzutsev, John A McCulloch, et al.

Cancer Cell|November 1, 2024

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trialDiwakar Davar, Robert M Morrison, Amiran K Dzutsev, et al.

Pageof 2

Search research articles

Showing results (11-20 of 15) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 15 results.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2018

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced MelanomaDiwakar Davar, Hong Wang, Joe-Marc Chauvin, et al.

The Journal of Clinical Investigation|March 22, 2022

Tim-3 mediates T cell trogocytosis to limit antitumor immunityOrnella Pagliano, Robert M Morrison, Joe-Marc Chauvin, et al.

Nature Medicine|March 1, 2022

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1John A McCulloch, Diwakar Davar, Richard R Rodrigues, et al.

Science (New York, N.Y.)|February 5, 2021

Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patientsDiwakar Davar, Amiran K Dzutsev, John A McCulloch, et al.

Cancer Cell|November 1, 2024

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trialDiwakar Davar, Robert M Morrison, Amiran K Dzutsev, et al.

Pageof 2